This is a paid press release. Contact the press release distributor directly with any inquiries.

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Catalyst Pharmaceuticals, Inc.

Wed, February 11, 2026 at 10:03 PM GMT+9 3 min read

In this article:

CPRX

-0.74%

Catalyst Pharmaceuticals, Inc.

The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET

CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) – Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 financial results after the market close on Wednesday, February 25, 2026.

Catalyst’s management team will host a conference call and webcast on Thursday, February 26, at 8:30 AM ET to discuss the Company’s financial results and provide a business update.

Conference Call & Webcast Details

The webcast will be accessible under the Investors section on the Company’s website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for at least 30 days following the date of the event.

About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

**Forward-Looking Statements **
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2024, its Quarterly Report on Form 10-Q for the third quarter of 2025, and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Story Continues  

Source: Catalyst Pharmaceuticals, Inc.

CONTACT: Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com

Terms and Privacy Policy

Privacy Dashboard

More Info